<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/legend-biotech-taps-novartis-veteran-zhang-ceo-2026-09-15/">Legend Biotech taps Novartis veteran Zhang as CEO</a>
    </div>

      <div class="me-0 me-md-5">
        Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an ​industry veteran to steer its expansion beyond blockbuster ‌cancer therapy Carvykti.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/legend-naming-novartis-executive-as-ceo-6a79fa0c">Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July</a>
    </div>

      <div class="me-0 me-md-5">
        Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/heart-disease-a-historic-strength-for-big-pharma-becomes-a-weakness-983f0062">Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness</a>
    </div>

      <div class="me-0 me-md-5">
        Heart disease remains humanity&#39;s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Barrons</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.barrons.com/articles/novartis-more-pain-on-the-way-5539f65e">Novartis: More Pain on the Way?</a>
    </div>

      <div class="me-0 me-md-5">
        The bad diagnoses just keep on coming for the Swiss drugmaker.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/transactional/novartis-investors-turn-spotlight-ma-after-trial-setbacks-2026-09-11/">Focus: Novartis investors turn spotlight on M&amp;A after trial setbacks</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis investors are set to step up scrutiny of the Swiss group&#39;s dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit ​its shares, raising concerns about its pipeline.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/world/major-novartis-shareholder-calls-board-shake-up-after-drug-trial-setbacks-2026-09-10/">Major Novartis shareholder calls for board shake-up after drug trial setbacks</a>
    </div>

      <div class="me-0 me-md-5">
        A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker&#39;s board to improve corporate governance after its shares suffered a record fall this week ​following back-to-back trial setbacks.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/09/08/jim-cramer-investors-focused-ai-stocks.html">Jim Cramer says investors are too focused on AI stocks. Here&#39;s where he says to look instead</a>
    </div>

      <div class="me-0 me-md-5">
        CNBC&#39;s Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy stocks.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/dyne-sarepta-shares-tumble-novartis-setback-weighs-muscle-disease-drug-2026-09-08/">Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis&#39; treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat rare ‌disease.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Novartis-ADR-US66987V1098/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>